D05.9

Clinical Causes: Genetic factors: Family history of breast cancer may increase risk. Hormonal influences: Extended exposure to estrogen without progesterone can promote abnormal cell growth. Environmental exposures: Certain environmental toxins may contribute to cellular changes. Lifestyle factors: Obesity, alcohol consumption, and lack of physical activity are linked to increased breast cancer risk. Age: Risk increases as women grow older, particularly after age 50. Previous breast diseases or conditions: Past benign or malignant breast conditions can predispose individuals.

Key Symptoms: Often asymptomatic, especially in early stages. Detection may occur through screening mammograms. In some cases, a lump or thickening in the breast can be felt. Changes in the size, shape, or appearance of the breast or nipple. Nipple discharge that is not related to breastfeeding. Unexplained skin changes or puckering of the breast tissue.

Diagnosis Path: Screening Mammography: Often the first step, capable of detecting microcalcifications or suspicious areas. Breast Biopsy: Essential to confirm the presence of abnormal cells. Types include core needle biopsy or surgical biopsy. Histopathological Examination: Laboratory analysis to distinguish between ductal or lobular CIS, though D05.9 specifies an unspecified type. Imaging Studies: Ultrasound or MRI may provide additional information about the extent of the disease. Laboratory Tests: Not typically used for diagnosis but may help in staging if invasive features are suspected.

Treatment Protocols: Surgical Removal: Usually involves a lumpectomy or excisional biopsy to remove the affected tissue. Radiation Therapy: Often recommended post-surgery to eradicate any remaining abnormal cells. Hormonal Therapy: May be considered if hormone receptor-positive disease, to block hormone effects promoting cell growth. Active Surveillance: In some cases, close monitoring with regular imaging and biopsies may be chosen, especially if surgery poses risks. Chemotherapy: Generally not indicated for CIS unless invasive features are identified. Targeted Therapy: Based on tumor receptor status, therapies may be utilized for invasive progression risk.